A tissue-based assay system for Alzheimer-specific degeneration and pathology
DE102004048462A1
Model system for testing pharmaceutical preparations for efficacy in inflammatory processes in the nervous system
EP1603583A2
Use of incense or hydrogenation products for preventing and/or treating a cerebral ischemia and/or cerebral traumatic lesion
DE10344284A1
Device and method for the automated performance of laboratory work steps
DE10337074A1
Use of the inhibitors of enzymes with activities of aminopeptidase N and / or dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of chronic neurodegenerative diseases
DE10331750A1
Therapy and/or prophylaxis of cranial-cerebral trauma, cerebral ischemia or Alzheimer's disease, using frankincense-based active agents, e.g. boswellic acid or hydrogenated derivatives
DE10322986A1
Vital mammalian heart tissue cells kept in vivo, processes for their production and cultivation and their use
DE10311921A1
Therapy and/or prophylaxis of cranial-cerebral trauma, cerebral ischemia or Alzheimer's disease, using frankincense-based active agents, e.g. boswellic acid or hydrogenated derivatives
DE10311920A1
Therapy and/or prophylaxis of cranial-cerebral trauma, cerebral ischemia or Alzheimer's disease, using frankincense-based active agents, e.g. boswellic acid or hydrogenated derivatives
DE10303229A1
Ambroxol and Angiotensin Converting Enzyme (ACE) inhibitors Drugs and their use in the treatment of neurodegenerative diseases
